Loading…

First-line treatment in metastatic colorectal cancer: Important or crucial?

First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of care. In addition to chemotherapy, patients may receive either bevacizumab, an anti-vascular endothelial growt...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) 2017-10, Vol.84, p.363-366
Main Authors:	Malka, David, Rotolo, Federico, Boige, Valérie
Format:	Article
Language:	English
Subjects:	5-Fluorouracil Antibodies Antineoplastic Combined Chemotherapy Protocols Bevacizumab Biological effects Camptothecin Cancer Chemotherapy Clinical trials Colorectal cancer Colorectal carcinoma Colorectal Neoplasms Comparative analysis Epidermal growth factor Epidermal growth factor receptors Folinic acid Humans Immunoglobulins Irinotecan Metastases Metastasis Monoclonal antibodies Organoplatinum Compounds Oxaliplatin Targeted cancer therapy Tumors Vascular endothelial growth factor
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c384t-ba6e11872fc6dde2377077d38b658f30d8c554b7a5f87d4ef9aba9eb02c0fd893
cites	cdi_FETCH-LOGICAL-c384t-ba6e11872fc6dde2377077d38b658f30d8c554b7a5f87d4ef9aba9eb02c0fd893
container_end_page	366
container_issue
container_start_page	363
container_title	European journal of cancer (1990)
container_volume	84
creator	Malka, David Rotolo, Federico Boige, Valérie
description	First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of care. In addition to chemotherapy, patients may receive either bevacizumab, an anti-vascular endothelial growth factor (VEGF)-directed antibody, or (in RAS wild-type tumours) anti-epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab). A decade has passed since the advent of these two classes of biological agents until the results of the two phase III studies comparing them to each other in combination with first-line chemotherapy.
doi_str_mv	10.1016/j.ejca.2017.09.001
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1942707205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804917312674</els_id><sourcerecordid>2033296817</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-ba6e11872fc6dde2377077d38b658f30d8c554b7a5f87d4ef9aba9eb02c0fd893</originalsourceid><addsrcrecordid>eNp9kMtq3TAURUVoSW4eP9BBMXTSiZ0j-SGpFEIIzQMudNKOhSwdg4xt3UhyIX-Tb-mXVZebZNBBRmey9mafRcgnChUF2l2OFY5GVwwor0BWAPSIbKjgsgTRsg9kA7KVpYBGnpDTGEcA4KKBY3LChGyY6PiGbG9diKmc3IJFCqjTjEsq3FLMmHRMOjlTGD_5gCbpqTB6MRi-FQ_zzoekl_T32YfChNU4PV2dk4-DniJevNwz8vv2x6-b-3L78-7h5npbmlo0qex1hzTvZIPprEVWcw6c21r0XSuGGqwwbdv0XLeD4LbBQepeS-yBGRiskPUZ-Xro3QX_uGJManbR4DTpBf0aFc3f5UoGbUa__IeOfg1LXqcY1DWTnaA8U-xAmeBjDDioXXCzDk-Kgtq7VqPau1Z71wqkyq5z6PNL9drPaN8ir3Iz8P0AYHbxx2FQ0TjMAq3b61TWu_f6_wF5A5B2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2033296817</pqid></control><display><type>article</type><title>First-line treatment in metastatic colorectal cancer: Important or crucial?</title><source>ScienceDirect Freedom Collection</source><creator>Malka, David ; Rotolo, Federico ; Boige, Valérie</creator><creatorcontrib>Malka, David ; Rotolo, Federico ; Boige, Valérie</creatorcontrib><description>First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of care. In addition to chemotherapy, patients may receive either bevacizumab, an anti-vascular endothelial growth factor (VEGF)-directed antibody, or (in RAS wild-type tumours) anti-epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab). A decade has passed since the advent of these two classes of biological agents until the results of the two phase III studies comparing them to each other in combination with first-line chemotherapy.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2017.09.001</identifier><identifier>PMID: 28942867</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>5-Fluorouracil ; Antibodies ; Antineoplastic Combined Chemotherapy Protocols ; Bevacizumab ; Biological effects ; Camptothecin ; Cancer ; Chemotherapy ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms ; Comparative analysis ; Epidermal growth factor ; Epidermal growth factor receptors ; Folinic acid ; Humans ; Immunoglobulins ; Irinotecan ; Metastases ; Metastasis ; Monoclonal antibodies ; Organoplatinum Compounds ; Oxaliplatin ; Targeted cancer therapy ; Tumors ; Vascular endothelial growth factor</subject><ispartof>European journal of cancer (1990), 2017-10, Vol.84, p.363-366</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright Elsevier Science Ltd. Oct 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-ba6e11872fc6dde2377077d38b658f30d8c554b7a5f87d4ef9aba9eb02c0fd893</citedby><cites>FETCH-LOGICAL-c384t-ba6e11872fc6dde2377077d38b658f30d8c554b7a5f87d4ef9aba9eb02c0fd893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28942867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malka, David</creatorcontrib><creatorcontrib>Rotolo, Federico</creatorcontrib><creatorcontrib>Boige, Valérie</creatorcontrib><title>First-line treatment in metastatic colorectal cancer: Important or crucial?</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of care. In addition to chemotherapy, patients may receive either bevacizumab, an anti-vascular endothelial growth factor (VEGF)-directed antibody, or (in RAS wild-type tumours) anti-epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab). A decade has passed since the advent of these two classes of biological agents until the results of the two phase III studies comparing them to each other in combination with first-line chemotherapy.</description><subject>5-Fluorouracil</subject><subject>Antibodies</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Bevacizumab</subject><subject>Biological effects</subject><subject>Camptothecin</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms</subject><subject>Comparative analysis</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>Folinic acid</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Irinotecan</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Organoplatinum Compounds</subject><subject>Oxaliplatin</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kMtq3TAURUVoSW4eP9BBMXTSiZ0j-SGpFEIIzQMudNKOhSwdg4xt3UhyIX-Tb-mXVZebZNBBRmey9mafRcgnChUF2l2OFY5GVwwor0BWAPSIbKjgsgTRsg9kA7KVpYBGnpDTGEcA4KKBY3LChGyY6PiGbG9diKmc3IJFCqjTjEsq3FLMmHRMOjlTGD_5gCbpqTB6MRi-FQ_zzoekl_T32YfChNU4PV2dk4-DniJevNwz8vv2x6-b-3L78-7h5npbmlo0qex1hzTvZIPprEVWcw6c21r0XSuGGqwwbdv0XLeD4LbBQepeS-yBGRiskPUZ-Xro3QX_uGJManbR4DTpBf0aFc3f5UoGbUa__IeOfg1LXqcY1DWTnaA8U-xAmeBjDDioXXCzDk-Kgtq7VqPau1Z71wqkyq5z6PNL9drPaN8ir3Iz8P0AYHbxx2FQ0TjMAq3b61TWu_f6_wF5A5B2</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Malka, David</creator><creator>Rotolo, Federico</creator><creator>Boige, Valérie</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201710</creationdate><title>First-line treatment in metastatic colorectal cancer: Important or crucial?</title><author>Malka, David ; Rotolo, Federico ; Boige, Valérie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-ba6e11872fc6dde2377077d38b658f30d8c554b7a5f87d4ef9aba9eb02c0fd893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>5-Fluorouracil</topic><topic>Antibodies</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Bevacizumab</topic><topic>Biological effects</topic><topic>Camptothecin</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms</topic><topic>Comparative analysis</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>Folinic acid</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Irinotecan</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Organoplatinum Compounds</topic><topic>Oxaliplatin</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malka, David</creatorcontrib><creatorcontrib>Rotolo, Federico</creatorcontrib><creatorcontrib>Boige, Valérie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malka, David</au><au>Rotolo, Federico</au><au>Boige, Valérie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First-line treatment in metastatic colorectal cancer: Important or crucial?</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2017-10</date><risdate>2017</risdate><volume>84</volume><spage>363</spage><epage>366</epage><pages>363-366</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of care. In addition to chemotherapy, patients may receive either bevacizumab, an anti-vascular endothelial growth factor (VEGF)-directed antibody, or (in RAS wild-type tumours) anti-epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab). A decade has passed since the advent of these two classes of biological agents until the results of the two phase III studies comparing them to each other in combination with first-line chemotherapy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28942867</pmid><doi>10.1016/j.ejca.2017.09.001</doi><tpages>4</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0959-8049
ispartof	European journal of cancer (1990), 2017-10, Vol.84, p.363-366
issn	0959-8049 1879-0852
language	eng
recordid	cdi_proquest_miscellaneous_1942707205
source	ScienceDirect Freedom Collection
subjects	5-Fluorouracil Antibodies Antineoplastic Combined Chemotherapy Protocols Bevacizumab Biological effects Camptothecin Cancer Chemotherapy Clinical trials Colorectal cancer Colorectal carcinoma Colorectal Neoplasms Comparative analysis Epidermal growth factor Epidermal growth factor receptors Folinic acid Humans Immunoglobulins Irinotecan Metastases Metastasis Monoclonal antibodies Organoplatinum Compounds Oxaliplatin Targeted cancer therapy Tumors Vascular endothelial growth factor
title	First-line treatment in metastatic colorectal cancer: Important or crucial?
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A14%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First-line%20treatment%20in%20metastatic%20colorectal%20cancer:%20Important%C2%A0or%20crucial?&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Malka,%20David&rft.date=2017-10&rft.volume=84&rft.spage=363&rft.epage=366&rft.pages=363-366&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2017.09.001&rft_dat=%3Cproquest_cross%3E2033296817%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c384t-ba6e11872fc6dde2377077d38b658f30d8c554b7a5f87d4ef9aba9eb02c0fd893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2033296817&rft_id=info:pmid/28942867&rfr_iscdi=true